Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

A Review on Plant Bioactive Compounds and Their Modes of Action Against Coronavirus Infection.

Tytuł:
A Review on Plant Bioactive Compounds and Their Modes of Action Against Coronavirus Infection.
Autorzy:
Remali J; Institute of Systems Biology (INBIOSIS), Universiti Kebangsaan Malaysia (UKM), Bangi, Malaysia.
Aizat WM; Institute of Systems Biology (INBIOSIS), Universiti Kebangsaan Malaysia (UKM), Bangi, Malaysia.
Źródło:
Frontiers in pharmacology [Front Pharmacol] 2021 Jan 11; Vol. 11, pp. 589044. Date of Electronic Publication: 2021 Jan 11 (Print Publication: 2020).
Typ publikacji:
Journal Article; Review
Język:
English
Imprint Name(s):
Original Publication: [Lausanne : Frontiers Media]
References:
Viruses. 2012 Mar;4(3):363-82. (PMID: 22590676)
Planta Med. 2008 May;74(6):661-6. (PMID: 18203051)
Proc Natl Acad Sci U S A. 2004 Jul 6;101(27):10012-7. (PMID: 15226499)
Proc Natl Acad Sci U S A. 2005 Aug 16;102(33):11876-81. (PMID: 16081529)
Evid Based Complement Alternat Med. 2012;2012:985151. (PMID: 23259003)
J Biol Chem. 2006 Feb 10;281(6):3198-203. (PMID: 16339146)
Antivir Ther. 2010;15(5):697-709. (PMID: 20710051)
Chem Biol Drug Des. 2019 Dec;94(6):2023-2030. (PMID: 31436895)
Nature. 2020 Mar;579(7798):270-273. (PMID: 32015507)
Amino Acids. 2007 Jul;33(1):129-35. (PMID: 16998715)
J Med Food. 2017 Feb;20(2):171-179. (PMID: 28061036)
Lancet. 2003 May 24;361(9371):1779-85. (PMID: 12781537)
N Engl J Med. 2003 May 15;348(20):1953-66. (PMID: 12690092)
J Assoc Physicians India. 1989 Oct;37(10):647. (PMID: 2632514)
MMWR Morb Mortal Wkly Rep. 2020 Feb 07;69(5):140-146. (PMID: 32027631)
Mil Med Res. 2020 Mar 13;7(1):11. (PMID: 32169119)
Lancet. 2020 Feb 15;395(10223):470-473. (PMID: 31986257)
J Ethnopharmacol. 2008 Oct 30;120(1):108-11. (PMID: 18762235)
J Mol Biol. 2003 Aug 29;331(5):991-1004. (PMID: 12927536)
J Virol. 2007 Aug;81(16):8722-9. (PMID: 17522231)
J Antimicrob Chemother. 2004 Jul;54(1):243-6. (PMID: 15190039)
Antiviral Res. 2016 Sep;133:165-77. (PMID: 27468951)
Curr Med Chem. 2021;28(15):2852-2886. (PMID: 32614740)
ACS Cent Sci. 2020 Mar 25;6(3):315-331. (PMID: 32226821)
Sci Total Environ. 2020 Jul 10;725:138277. (PMID: 32278175)
Biochim Biophys Acta. 2011 Feb;1808(2):510-5. (PMID: 20478263)
J Chem Theory Comput. 2009 Sep 8;5(9):2503-13. (PMID: 26616628)
Eur Biophys J. 2010 Jun;39(7):1041-2. (PMID: 19672588)
Biosci Trends. 2009 Aug;3(4):124-6. (PMID: 20103835)
Nat Rev Microbiol. 2009 Mar;7(3):226-36. (PMID: 19198616)
Nature. 2003 Nov 27;426(6965):450-4. (PMID: 14647384)
Avian Pathol. 2011 Oct;40(5):491-8. (PMID: 21848486)
Phytother Res. 2008 Feb;22(2):141-8. (PMID: 17886224)
Antiviral Res. 2005 Jul;67(1):18-23. (PMID: 15885816)
Expert Rev Vaccines. 2016 Sep;15(9):1123-34. (PMID: 26985862)
Biomolecules. 2020 Feb 27;10(3):. (PMID: 32120929)
Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12540-5. (PMID: 16894145)
Chem Pharm Bull (Tokyo). 1982 Dec;30(12):4548-53. (PMID: 7168874)
FEBS Lett. 2003 Oct 23;553(3):262-70. (PMID: 14572635)
Nature. 2013 Mar 14;495(7440):251-4. (PMID: 23486063)
Adv Virus Res. 2006;66:193-292. (PMID: 16877062)
Mol Biol Cell. 2004 Aug;15(8):3591-604. (PMID: 15194809)
FEBS Lett. 2003 Oct 23;553(3):451-6. (PMID: 14572668)
Virol J. 2011 Oct 04;8:460. (PMID: 21967756)
J Ethnopharmacol. 2008 Oct 28;119(3):420-33. (PMID: 18725280)
Phytother Res. 2011 Mar;25(3):338-42. (PMID: 20677175)
Peptides. 2006 Apr;27(4):622-5. (PMID: 16242214)
Science. 2003 Jun 13;300(5626):1763-7. (PMID: 12746549)
Antiviral Res. 2009 Apr;82(1):73-81. (PMID: 19428598)
J Gen Virol. 2003 Sep;84(Pt 9):2305-2315. (PMID: 12917450)
Expert Opin Ther Targets. 2017 Feb;21(2):131-143. (PMID: 27936982)
J Integr Med. 2020 Mar;18(2):152-158. (PMID: 32113846)
Annu Rev Cell Dev Biol. 1996;12:575-625. (PMID: 8970738)
Dtsch Arztebl Int. 2020 Mar 27;117(13):213-219. (PMID: 32343658)
J Enzyme Inhib Med Chem. 2020 Dec;35(1):145-151. (PMID: 31724441)
Lancet. 2004 Mar 20;363(9413):938-47. (PMID: 15043961)
Biochemistry. 2005 Aug 2;44(30):10349-59. (PMID: 16042412)
Phytomedicine. 2011 Mar 15;18(5):384-6. (PMID: 21036571)
Cell Host Microbe. 2020 Mar 11;27(3):325-328. (PMID: 32035028)
Expert Rev Vaccines. 2018 Aug;17(8):677-686. (PMID: 30058403)
Expert Rev Anti Infect Ther. 2006 Aug;4(4):549-61. (PMID: 17009935)
Virus Res. 2019 Nov;273:197767. (PMID: 31560964)
Lancet. 2003 Jun 14;361(9374):2045-6. (PMID: 12814717)
Antiviral Res. 2007 May;74(2):92-101. (PMID: 16730806)
Phytomedicine. 2021 May;85:153361. (PMID: 33485605)
J Clin Virol. 2008 Feb;41(2):122-8. (PMID: 18036887)
Phytother Res. 2008 Jun;22(6):709-24. (PMID: 18446848)
J Virol. 2014 Nov;88(22):13221-30. (PMID: 25187545)
FEBS Lett. 2003 Sep 18;552(1):61-7. (PMID: 12972153)
Lancet. 2020 Feb 15;395(10223):507-513. (PMID: 32007143)
Integr Cancer Ther. 2020 Jan-Dec;19:1534735420912811. (PMID: 32178547)
Biomolecules. 2019 Nov 04;9(11):. (PMID: 31690059)
Nat Prod Commun. 2012 Nov;7(11):1415-7. (PMID: 23285797)
FEBS Lett. 2003 Sep 18;552(1):47-53. (PMID: 12972151)
Avicenna J Phytomed. 2016 Jul-Aug;6(4):458-267. (PMID: 27516987)
J Med Chem. 2005 Feb 24;48(4):1256-9. (PMID: 15715493)
Trends Microbiol. 2018 Oct;26(10):865-876. (PMID: 29759926)
J Med Chem. 2004 Feb 26;47(5):1079-80. (PMID: 14971887)
Foods. 2020 Aug 01;9(8):. (PMID: 32752217)
PLoS One. 2013 Apr 16;8(4):e61007. (PMID: 23613770)
Rev Bras Farmacogn. 2019 Jan-Feb;29(1):111-124. (PMID: 32287507)
Wien Med Wochenschr. 2007;157(13-14):331-6. (PMID: 17704982)
J Ethnopharmacol. 2008 Jun 19;118(1):79-85. (PMID: 18479853)
Science. 2003 May 30;300(5624):1399-404. (PMID: 12730501)
Respir Res. 2020 Aug 27;21(1):224. (PMID: 32854739)
J Virol. 2008 Sep;82(17):8887-90. (PMID: 18562523)
J Biol Chem. 2020 May 15;295(20):6785-6797. (PMID: 32284326)
J Clin Virol. 2004 Sep;31(1):69-75. (PMID: 15288617)
J Integr Med. 2020 Mar;18(2):87-88. (PMID: 32122812)
Antiviral Res. 2005 Oct;68(1):36-42. (PMID: 16115693)
J Virol. 2005 Dec;79(24):15199-208. (PMID: 16306591)
Annu Rev Pharmacol Toxicol. 1980;20:259-84. (PMID: 6992699)
Front Microbiol. 2020 Feb 28;11:298. (PMID: 32265848)
Asian Pac J Trop Med. 2016 Jan;9(1):1-7. (PMID: 26851778)
Contributed Indexing:
Keywords: COVID-19; SARS; Traditional Chinese medicine (TCM); drug; herb; medicinal plant; natural products; viral infection
Entry Date(s):
Date Created: 20210201 Latest Revision: 20231110
Update Code:
20240104
PubMed Central ID:
PMC7845143
DOI:
10.3389/fphar.2020.589044
PMID:
33519449
Czasopismo naukowe
The rapid outbreak of coronavirus disease 2019 (COVID-19) has demonstrated the need for development of new vaccine candidates and therapeutic drugs to fight against the underlying virus, severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). Currently, no antiviral treatment is available to treat COVID-19 as treatment is mostly directed to only relieving the symptoms. Retrospectively, herbal medicinal plants have been used for thousands of years as a medicinal alternative including for the treatment of various viral illnesses. However, a comprehensive description using various medicinal plants in treating coronavirus infection has not to date been described adequately, especially their modes of action. Most other reports and reviews have also only focused on selected ethnobotanical herbs such as Traditional Chinese Medicine, yet more plants can be considered to enrich the source of the anti-viral compounds. In this review, we have screened and identified potential herbal medicinal plants as anti-coronavirus medication across major literature databases without being limited to any regions or ethnobotanic criteria. As such we have successfully gathered experimentally validated in vivo , in vitro, or in silico findings of more than 30 plants in which these plant extracts or their related compounds, such as those of Artemisia annua L., Houttuynia cordata Thunb. , and Sambucus formosana Nakai, are described through their respective modes of action against specific mechanisms or pathways during the viral infection. This includes inhibition of viral attachment and penetration, inhibition of viral RNA and protein synthesis, inhibition of viral key proteins such as 3-chymotrypsin-like cysteine protease (3CL pro ) and papain-like protease 2 (PL pro ), as well as other mechanisms including inhibition of the viral release and enhanced host immunity. We hope this compilation will help researchers and clinicians to identify the source of appropriate anti-viral drugs from plants in combating COVID-19 and, ultimately, save millions of affected human lives.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2021 Remali and Aizat.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies